{"article_title": "2015 Will Be A Watershed Moment For Biosimilars", "article_keywords": ["abbreviated", "biosimilars", "watershed", "pathway", "surrounding", "moment", "york", "act", "2015", "bpcia", "theto", "view"], "article_url": "http://www.law360.com/articles/617346/2015-will-be-a-watershed-moment-for-biosimilars", "article_text": "2015 Will Be A Watershed Moment For Biosimilars\n\nLaw360, New York (February 3, 2015, 3:07 PM ET) -- The Biologics Price Competition and Innovation Act, enacted as a subsection of the Affordable Care Act and signed into law in March 2010, was designed to create an abbreviated pathway for U.S. Food and Drug Administration approval of biosimilar biologic drugs.[1] Such an abbreviated pathway had existed since 1984 for generic small-molecule drugs via the Hatch-Waxman Act,[2] but the BPCIA broke new ground for large-molecule, complex biologics.\n\n\n\nDespite the fanfare surrounding passage of the BPCIA, it was not until four years later, in 2014, that the...\n\nTo view the full article, register now.", "article_metadata": {"description": "The filing of the first Section 262(k) applications in 2014 under the Biologics Price Competition and Innovation Act represents the tip of the iceberg for biosimilars as further guidance from the U.S. Food and Drug Administration will now almost certainly be required on the important issues of naming and labeling for biosimilars as well interchangeability, says Thomas Wintner of Mintz Levin Cohn Ferris Glovsky and Popeo PC.", "csrf-token": "EprC4/HD/uUIG1+kyukmsIhDveePznXcZPXD1c4gY7pj5c7mrBMqphAT5IExRbxn7eDSe/tsoL3PtINGXl+Ohw==", "og": {"url": "http://www.law360.com/articles/617346/2015-will-be-a-watershed-moment-for-biosimilars", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "2015 Will Be A Watershed Moment For Biosimilars - Law360"}, "csrf-param": "authenticity_token", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/617346/2015-will-be-a-watershed-moment-for-biosimilars", "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af36914bd0286fcfe26\"", "article_summary": "Despite the fanfare surrounding passage of the BPCIA, it was not until four years later, in 2014, that the...To view the full article, register now.\n[1] Such an abbreviated pathway had existed since 1984 for generic small-molecule drugs via the Hatch-Waxman Act,[2] but the BPCIA broke new ground for large-molecule, complex biologics.\n2015 Will Be A Watershed Moment For BiosimilarsLaw360, New York (February 3, 2015, 3:07 PM ET) -- The Biologics Price Competition and Innovation Act, enacted as a subsection of the Affordable Care Act and signed into law in March 2010, was designed to create an abbreviated pathway for U.S. Food and Drug Administration approval of biosimilar biologic drugs."}